Biologix Hair Inc. Appoints Ken Zadoorian to Board of Directors

Biologix Hair Inc. Appoints Ken Zadoorian to Board of Directors

Toronto, Ontario – May 13, 2013 – Biologix Hair Inc. (OTCBB: BLGX; OTCQB: BLGX) has appointed Ken Zadoorian to the Company's Board of Directors.

Ken Zadoorian has built a long track record as a successful executive with an extensive background in large organizations and smaller start-ups as well as experience managing engineering, manufacturing, information technology, community relations and sales. Ken has proven success in building and developing organizations as well as mergers and acquisitions and has offered business consulting through Axeo Consulting and Scottsdale Consulting.

During his 25-plus years at Eli Lilly & Company, Mr. Zadoorian held several management positions including director of Human Resources, Worldwide Manufacturing and Engineering and director of Human Resources, Corporate Staff Components, each position having responsibility for several thousand employees.

Additionally, Ken has served as vice president of operations for American Optical Services/Exela Hearing Services; vice president, Operations and Human Resources for Zounds, Inc.; COO of Superior Home Services; vice president of Human Resources for Cox Communications; senior vice president of Operations, Facilities and Human Resources for PCS Health Systems; and vice president of Administration for Advanced Cardiovascular Systems.

Ken's formal education has included a B.S. in Industrial Management from Purdue University and the Executive's MBA Consortium at Indiana University.  He has served as Chairman of the Board for Boys & Girls Clubs of Scottsdale, Board Director for Maricopa Community Colleges Foundation and Board Director for the Cal Ripken Sr. Foundation.

Biologix CEO and Chairman Ron Holland stated: "Ken Zadoorian is a welcome addition to the Biologix Hair Inc. Board of Directors. With his success in corporate executive leadership, particularly within the pharmaceutical industry, and extensive consulting experience, I'm sure Ken will offer valuable contributions to the Company."

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.